๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Ozurdex clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our Denmark and Mexico registers that name Ozurdex as an intervention. Synced 27 Sep 2026
2Current trials
2Recruiting now
2Lead sponsors
2Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards
At a glance

Ozurdex is named as an intervention in 2 current clinical trials in our Denmark and Mexico registers. 2 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Rigshospitalet, Denmark (1). The most-studied condition is Informed Consent.

Trials by status

  • Recruiting2100%

Trials by phase

  • Observational150%
  • Phase 4150%
01

Clinical trials of Ozurdex

2 trials
StudyPhaseStatusLead sponsorRegisters
Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection
NCT06268704 · ClinicalTrials.gov ↗ · Sacroiliac Joint Dysfunction, Sacro-Iliac Spondylosis
Phase 4 Recruiting University of New Mexico Mexico
Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections
NCT06894017 · ClinicalTrials.gov ↗ · Informed Consent, Preference, Patient
Observational Recruiting Rigshospitalet, Denmark Denmark

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Ozurdex

4 conditions
Informed Consent1Preference, Patient1Sacroiliac Joint Dysfunction1Sacro-Iliac Spondylosis1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Rigshospitalet, Denmark1
University of New Mexico1
04

By country register

RegisterTrialsRecruiting
Clinical trials in Denmark11
Clinical trials in Mexico11

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Ozurdex trials

How many clinical trials are testing Ozurdex?

2 current trials in our Denmark and Mexico registers name Ozurdex as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Ozurdex trials recruiting patients?

Yes. 2 of the 2 trials are recruiting: 1 with sites in Denmark and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Ozurdex clinical trials?

Rigshospitalet, Denmark (1) and University of New Mexico (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ozurdex works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Ozurdex works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ozurdex (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.